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Background
The introduction of a microarray containing 112 different
components in the management of allergic patients has sig-
nificantly modified the diagnosis and the treatment in poly-
sensitized patients (Sastre, 2012, Passalacqua, 2013),
because of the large number of added values generated by
this approach in comparison with other diagnostics based
on extractive – non purified –allergens. However, microar-
ray interpretation is sometimes challenging, for the high
number of possible combinations of 112 different allergens,
the very large number of interactions between different
components, the presence of either genuine or cross-react-
ing components, the presence of both inhalant and food
allergens (Melioli e Canonica, 2012).
Methods
An expert system, based on Flex, a language related to
Prolog, has been developed. The characteristics of the dif-
ferent components and the rules governing the relation-
ships between allergens were obtained from medical
literature and specialized web sites. The inputs of the
expert system are the age and the diseases of the patient,
Skin Prick Tests and specific IgE results (when available)
and microarray (ISAC) results.
Results
The expert system output is represented by a text file con-
taining patient’s identification and the description of the
general situation (mono or poly-sensitization, cross- or co-
sensitization). The patient’s phenotype (Melioli, 2013) and
its relationship with expected immunotherapy results
(Schmid-Grendelmeier, 2010) are also shown. A list of
warnings, related to a sensitization to potentially danger-
ous components (such as LTPs, Peanuts etc.) is presented.
At the end of the introduction, all positive components
(inhalants, food, latex and venoms) are listed and com-
mented. Then, families of positive cross-reacting compo-
nents (such as PR-10, profilins, tropomyosins etc) are
discussed. A special section (termed “post molecular ana-
mnesis”) suggest the doctor any clinical questions that
should arise from the microarray interpretation (such as
the mite-shrimps syndrome in the presence of a sensitiza-
tion to Der p 10). Finally, two other sections (the first
focused on therapeutic suggestions for inhalant allergy
and the second of possible discrepancies between SPT
/sIgE and microarray results) are available. Of note, the
final report has hyperlinks to a dedicated web site to add
further information about allergens, component, diseases
etc. The “in silico” validation of the expert system (Aller-
genius v4.2) was successful and the clinical validation in
progress.
Conclusions
The potential impact of this technology in the manage-
ment of complex polysensitized patients, namely a more
proper prescription of Allergen Immunotherapy, could
be really relevant.
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